Attached files
| file | filename |
|---|---|
| EX-99.6 - EXHIBIT 99.6 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-6.htm |
| EX-99.5 - EXHIBIT 99.5 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-5.htm |
| EX-99.4 - EXHIBIT 99.4 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-4.htm |
| EX-99.2 - EXHIBIT 99.2 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-2.htm |
| EX-99.1 - EXHIBIT 99.1 - ALBANY MOLECULAR RESEARCH INC | v440429_ex99-1.htm |
| 8-K - FORM 8-K - ALBANY MOLECULAR RESEARCH INC | v440429_8k.htm |
Exhibit 99.3
Balance sheet 31.12.2013
| (in thousands of Euro) | 31 December 2013 Consolidated Lauro 57 IFRS | Deconsolidation Lauro 57 | 31 December 2013 Consolidated Euticals | ADJ R&D | 31 December 2013 Consolidated Euticals ADJ | |||||||||||||||
| Intangible assets | 116,282 | (91,841 | ) | 24,441 | (7,233 | ) | 17,208 | |||||||||||||
| Tangible assets | 86,426 | 0 | 86,426 | 86,426 | ||||||||||||||||
| Deferred tax assets | 6,299 | - | 6,299 | 2,291 | 8,590 | |||||||||||||||
| Other non-current assets | 1,844 | (0 | ) | 1,844 | 1,844 | |||||||||||||||
| Total non-current assets | 210,851 | (91,841 | ) | 119,010 | (4,942 | ) | 114,069 | |||||||||||||
| Inventories | 73,479 | (1 | ) | 73,478 | 73,478 | |||||||||||||||
| Trade receivables | 50,198 | (172 | ) | 50,026 | 50,026 | |||||||||||||||
| Current tax receivables | 1,954 | (294 | ) | 1,660 | 1,660 | |||||||||||||||
| Other current assets | 3,541 | (0 | ) | 3,541 | 3,541 | |||||||||||||||
| Cash and cash equivalents | 15,148 | (2,309 | ) | 12,839 | 12,839 | |||||||||||||||
| Total current assets | 144,320 | (2,776 | ) | 141,544 | - | 141,544 | ||||||||||||||
| Asset of disposal group classified as held for sale | 1,624 | - | 1,624 | 1,624 | ||||||||||||||||
| Total assets | 356,795 | (94,617 | ) | 262,178 | (4,942 | ) | 257,236 | |||||||||||||
| Share capital | 50,000 | (15,629 | ) | 34,371 | 34,371 | |||||||||||||||
| Share premium reserve | 167,500 | (143,109 | ) | 24,391 | 24,391 | |||||||||||||||
| Other reserves | (10,229 | ) | 38,058 | 27,829 | 27,829 | |||||||||||||||
| Profit (loss) carried forward | (20,452 | ) | (11,317 | ) | (31,769 | ) | (4,198 | ) | (35,967 | ) | ||||||||||
| Profit (loss) for the period | (8,404 | ) | 7,366 | (1,038 | ) | (744 | ) | (1,782 | ) | |||||||||||
| Net equity | 178,415 | (124,631 | ) | 53,784 | (4,942 | ) | 48,843 | |||||||||||||
| Non-current financial liabilities | 1,552 | 20,000 | 21,552 | 21,552 | ||||||||||||||||
| Liabilities for employees’ benefits | 10,126 | (0 | ) | 10,126 | 10,126 | |||||||||||||||
| Non-current provisions for risks and charges | 6,449 | (0 | ) | 6,449 | 6,449 | |||||||||||||||
| Other non-current liabilities | - | - | - | - | ||||||||||||||||
| Deferred tax liabilities | 582 | 0 | 582 | 582 | ||||||||||||||||
| Total non-current liabilities | 18,709 | 20,000 | 38,709 | - | 38,709 | |||||||||||||||
| Current financial liabilities | 101,783 | 10,499 | 112,282 | 112,282 | ||||||||||||||||
| Trade payables | 38,784 | (315 | ) | 38,469 | 38,469 | |||||||||||||||
| Tax payables | 3,209 | (137 | ) | 3,072 | 3,072 | |||||||||||||||
| Current provisions for risks and charges | 1,325 | (0 | ) | 1,325 | 1,325 | |||||||||||||||
| Other current payables | 14,570 | (33 | ) | 14,537 | 14,537 | |||||||||||||||
| Total current liabilities | 159,671 | 10,014 | 169,685 | - | 169,685 | |||||||||||||||
| Total liabilities | 178,380 | 30,014 | 208,394 | - | 208,394 | |||||||||||||||
| Liabilities of disposal group classified as held for sale | - | - | - | - | ||||||||||||||||
| Total equity and liabilities | 356,795 | (94,617 | ) | 262,178 | (4,942 | ) | 257,236 | |||||||||||||
Profit & Loss 31.12.2013
| (in thousands of Euro) | 31 December 2013 Consolidated Lauro 57 IFRS | Deconsolidation Lauro 57 | 31 December 2013 Consolidated Euticals | ADJ R&D | 31 December 2013 Consolidated Euticals ADJ | |||||||||||||||
| Revenues | 201,809 | 0 | 201,809 | 201,809 | ||||||||||||||||
| Other revenue and income | 1,093 | (195 | ) | 898 | 898 | |||||||||||||||
| Total Revenues and incomes | 202,902 | (195 | ) | 202,707 | 202,707 | |||||||||||||||
| Raw, ancillary and consumable materials and goods | (90,550 | ) | - | (90,550 | ) | (90,550 | ) | |||||||||||||
| Service costs and costs of third-party assets | (44,947 | ) | 361 | (44,586 | ) | (44,586 | ) | |||||||||||||
| Employee expenses | (54,978 | ) | - | (54,978 | ) | (54,978 | ) | |||||||||||||
| Other operating expenses | (3,559 | ) | 2 | (3,557 | ) | (3,557 | ) | |||||||||||||
| Change in inventories | 8,868 | - | 8,868 | 8,868 | ||||||||||||||||
| Capitalization of internal costs | 3,647 | (0 | ) | 3,647 | (3,072 | ) | 575 | |||||||||||||
| Depreciation, Amortization and Asset value adjustments | (21,998 | ) | 7,673 | (14,325 | ) | 1,973 | (12,352 | ) | ||||||||||||
| Total operating costs | (203,517 | ) | 8,036 | (195,481 | ) | (1,099 | ) | (196,581 | ) | |||||||||||
| Operating profit | (615 | ) | 7,841 | 7,226 | (1,099 | ) | 6,126 | |||||||||||||
| EBITDA | 21,383 | 168 | 21,551 | (3,072 | ) | 18,478 | ||||||||||||||
| Financial income | 8 | (3 | ) | 5 | 5 | |||||||||||||||
| Financial expenses | (6,098 | ) | (600 | ) | (6,698 | ) | (6,698 | ) | ||||||||||||
| Extraordinary Income/ (Expenses) | - | - | - | - | ||||||||||||||||
| Profit (loss) before taxes | (6,705 | ) | 7,238 | 533 | (1,099 | ) | (566 | ) | ||||||||||||
| Income taxes | (1,699 | ) | 128 | (1,571 | ) | 355 | (1,216 | ) | ||||||||||||
| Net profit (loss) from operations | (8,404 | ) | 7,366 | (1,038 | ) | (744 | ) | (1,782 | ) | |||||||||||